Shuanglingubensan, an anti-cancer traditional Chinese medicine has gained approval for clinical use from the Food and Drug Administration of America, and the clinic research will be carried out at the Sloan-Kettering Cancer Center in the US. The plan for clinic research is to be finalized in April and the research will begin in June, confirmed China's State Administration of Traditional Chinese Medicine.

The FDA approval signifies recognition for fundamental and clinic research for the Shuanglinggubensan carried out in China, said Ren Xubin, Director of the Tumor Pharmacology and Radioactive Treatment Society of China and a tutor for doctoral students with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

According to experts, Shuanglinggubensan has evident effect in alleviating side effect caused by radioactive treatment. The producer of the drug, Shanghai Green Valley Group has been admitted by the American Cancer Control Association. Using precious herb glossy ganoderma as main ingredient, Shuanglinggubensan contains anti-cancer ingredient and has become the sole anti-cancer TCM listed in the UN purchasing directory in 2004, introduced Lin Zhibin, president of Pharmacology Society of China and a tutor for doctoral students with the Medical Department of Peking University.